Rani Therapeutics Holdings, Inc. (RANI)
2025-06-30 | 2025-03-31 | |||
|---|---|---|---|---|
| Contract revenue | - | 172 | ||
| Research and development | 5,505 | 6,570 | ||
| General and administrative | 5,000 | 5,615 | ||
| Total operating expenses | 10,505 | 12,185 | ||
| Loss from operations | -10,505 | -12,013 | ||
| Interest expense and other, net | 877 | 943 | ||
| Interest income and other, net | 158 | 218 | ||
| Net loss | -11,224 | -12,738 | ||
| Net loss attributable to non-controlling interest | -4,532 | -5,474 | ||
| Net loss attributable to rani therapeutics holdings, inc | -6,692 | -7,264 | ||
| Net loss per class a common share attributable to rani therapeutics holding, inc., basic | -0.18 | -0.22 | ||
| Net loss per class a common share attributable to rani therapeutics holding, inc., diluted | -0.18 | -0.22 | ||
| Weighted-average share outstanding basic | 36,542,000 | 33,440,000 | ||
| Weighted-average share outstanding diluted | 36,542,000 | 33,440,000 | ||